Guo Xinjing, Lou Jia, Wang Fazhan, Fan Daoyang, Qin Zhihai
Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Department of Orthopedic, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Front Pharmacol. 2022 Jun 21;13:924387. doi: 10.3389/fphar.2022.924387. eCollection 2022.
Osteoarthritis (OA) is the most common type of arthritis and the leading cause of disability globally. It tends to occur in middle age or due to an injury or obesity. OA occurs with the onset of symptoms, including joint swelling, joint effusion, and limited movement at a late stage of the disease, which leads to teratogenesis and loss of joint function. During the pathogenesis of this degenerative joint lesion, several local inflammatory responses are activated, resulting in synovial proliferation and pannus formation that facilitates the destruction of the bone and the articular cartilage. The commonly used drugs for the clinical diagnosis and treatment of OA have limitations such as low bioavailability, short half-life, poor targeting, and high systemic toxicity. With the application of nanomaterials and intelligent nanomedicines, novel nanotherapeutic strategies have shown more specific targeting, prolonged half-life, refined bioavailability, and reduced systemic toxicity, compared to the existing medications. In this review, we summarized the recent advancements in new nanotherapeutic strategies for OA and provided suggestions for improving the treatment of OA.
骨关节炎（OA）是最常见的关节炎类型，也是全球致残的主要原因。它往往发生在中年，或者由于受伤或肥胖所致。OA在疾病后期出现症状，包括关节肿胀、关节积液和活动受限，这会导致致畸并丧失关节功能。在这种退行性关节病变的发病机制中，会激活几种局部炎症反应，导致滑膜增生和血管翳形成，从而促进骨骼和关节软骨的破坏。用于OA临床诊断和治疗的常用药物存在局限性，如生物利用度低、半衰期短、靶向性差和全身毒性高。随着纳米材料和智能纳米药物的应用，与现有药物相比，新型纳米治疗策略显示出更具特异性的靶向性、更长的半衰期、更高的生物利用度和更低的全身毒性。在本综述中，我们总结了OA新型纳米治疗策略的最新进展，并为改善OA治疗提供了建议。
